From the Journals

New MS subtype shows absence of cerebral white matter demyelination


 

FROM LANCET NEUROLOGY

The study was funded by the U.S. National Institutes of Health and National Multiple Sclerosis Society. One author was an employee of Renovo Neural, and three authors were employees of Biogen. One author declared a pending patent related to automated lesion segmentation from MRI images, and four authors declared funding, fees, and non-financial support from pharmaceutical companies.

SOURCE: Trapp B et al. Lancet Neurol. 2018 Aug 21. doi: 10.1016/ S1474-4422(18)30245-X.

Pages

Recommended Reading

Ozanimod May Provide Better MS Outcomes Than Interferon Beta
MDedge Neurology
Research supports cannabis in MS, but legal, clinical pictures are murky
MDedge Neurology
Lipid Metabolism May Be a Therapeutic Target in MS
MDedge Neurology
A Rational Approach to Starting, Stopping, and Switching DMTs
MDedge Neurology
Investigators Describe the MS Prodrome
MDedge Neurology
Fitbit Flex is feasible, provides nuanced step count data in MS patients
MDedge Neurology
Conference News Roundup—European Academy of Neurology
MDedge Neurology
Treatment of relapsing progressive MS may reduce disability progression
MDedge Neurology
Aspirin May Be an Effective Pretreatment for Exercise in Patients With MS
MDedge Neurology
New MS criteria may create more false positives
MDedge Neurology